➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Merck
Johnson and Johnson
Colorcon
Dow

Last Updated: July 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,388,134


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,388,134 protect, and when does it expire?

Patent 9,388,134 protects ENTRESTO and is included in one NDA.

Protection for ENTRESTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-three patent family members in thirty-three countries.

Summary for Patent: 9,388,134
Title:Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Abstract: A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Inventor(s): Feng; Lili (Pine Brook, NJ), Godtfredsen; Sven Erik (Chatham, NJ), Sutton; Paul Allen (Parsippany, NJ), Prashad; Mahavir (Montville, NJ), Girgis; Michael J. (Montville, NJ), Hu; Bin (Green Brook, NJ), Liu; Yugang (Bridgewater, NJ), Blacklock; Thomas J. (East Hanover, NJ), Karpinski; Piotr Henryk (Lincoln Park, NJ)
Assignee: NOVARTIS, AG (Basel, CH)
Application Number:14/311,788
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,388,134
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,388,134

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-001 Jul 7, 2015 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-002 Jul 7, 2015 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Novartis Pharms Corp ENTRESTO sacubitril; valsartan TABLET;ORAL 207620-003 Jul 7, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Medtronic
AstraZeneca
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.